Tasly Holding Group

What Tasly Holding Group does

Tasly Holding Group Co., Ltd. is a privately held, high-tech Chinese conglomerate founded in 1994 in Tianjin, focused on the "Great Health" (pan-health) industry. The group operates through a portfolio of wholly-owned subsidiaries and one listed entity (Tasly Pharma Group, stock code 600535 on the Shanghai Stock Exchange) spanning bio-pharmaceuticals, wellness & lifestyle products, digital health services, and capital investment. Bio-pharmaceutical operations center on modern Chinese medicine, chemical APIs, and biological innovation drugs in cardio-cerebrovascular, tumor immunity, digestion/metabolism, and neuroscience therapeutic areas, with 16 bio-pharmaceutical products and the regulatory distinction of Compound Danshen Dripping Pill — the first traditional Chinese medicine to complete FDA Phase III clinical trials. Secondary verticals include Guotai Liquor (second-largest government-licensed Maotai-flavor liquor producer in Maotai Town with annual output near 10,000 tons and brand value over RMB 200 billion in 2024), Tasly Deepure biological Pu'er tea, Jilin Tasly mineral water using patented small-molecule clustering technology, Digital Herbal Testing services (CMA/CNAS accredited), and Juzhi Great Health digital health platform with internet hospital and chronic disease management.

The group's technology stack includes the Digital Materia Medica AI model for TCM R&D (built on Huawei Cloud Pangu Models 5.0), intelligent brewing systems for Maotai-flavor liquor, digital herbal tracing, and 4-D integrated health management solutions across prevention, diagnosis, treatment, and rehabilitation. Revenue is generated across multiple streams: pharmaceutical sales (one-time licensing and drug sales), physical product sales (liquor, tea, mineral water), digital health subscription services (chronic disease management), and capital management fees (Tasly Capital VC/PE/M&A funds). Distribution combines direct enterprise field sales (Tasly Pharma), channel partners (Tokyo Lifestyle master distributor agreement from March 2026), international subsidiaries across 11+ countries (Japan, Korea, Malaysia, Indonesia, Vietnam, USA, Canada, Australia, South Africa, Germany), and proprietary e-commerce platforms (Digital Herbal, Juzhi Great Health). Customer segments include healthcare providers and patients, consumer wellness buyers, advanced therapeutics seekers (cell & gene therapy), international distribution partners, and capital investors.

Geographically, the group operates a research and commercial footprint across Tianjin, Guizhou, Hebei, Yunnan, Jilin, Shaanxi, Hong Kong, Japan, Australia, the United States, Canada, South Korea, Malaysia, Indonesia, Vietnam, South Africa, and Germany, with 20+ global research centers and 11 production bases throughout China. The group has received four National Science and Technology Progress Awards, was listed in the 2024 China Top 500 Private Enterprises and Top 500 Private Manufacturers, and marked its 30th anniversary in 2024 alongside a strategic partnership with China Resources Pharmaceutical Group (CRP) for Chinese medicinal formulation innovation. Founder Yan XiJun has remained president since founding.

Name

Tasly Holding Group

Legal name

Tasly Holding Group Co., Ltd.

Website

https://en.tasly.com

Company type

Private

Founded year

1994

Operating status

Operating

Headcount range

10,001+ employees

Short description

Tasly Holding Group is a privately held, Tianjin-based high-tech Chinese conglomerate operating across the Great Health industry through bio-pharmaceuticals (including FDA Phase III-approved Compound Danshen Dripping Pill), consumer wellness products (Guotai Maotai-flavor liquor, Pu'er tea, mineral water), digital health services, and capital investment, serving patients, healthcare providers, and consumers globally across 11+ countries.

Ownership category

akta.pro rank

Product category

Traditional Chinese Medicine Pharmaceuticals

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (42421)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro industry

PRIMARYHLAIABAD

Oral Solid Dose (OSD) Generics

Healthcare & Life Sciences/Pharmaceuticals/Generic Pharmaceuticals

SECONDARYCRADAHAD

Ready-to-Drink (RTD) Tea

Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Non-Alcoholic Beverages (Coffee, Tea, Soft Drinks, Water)

SECONDARYCRAFAEAK

Health & Pharmacy Omnichannel

Consumer Products & Retail/E-commerce & Marketplaces/Omnichannel Retail E-commerce

Keywords

• Traditional Chinese medicine
• Pharmaceutical manufacturing
• Health supplements
• Digital health services
• Liquor production

Headquarters

HQ city

Tianjin

HQ country

China

HQ region

Asia

Offices15 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Bio-pharmaceutical Products: Revenue from pharmaceutical products including modern Chinese medicine, chemical medicine, and biological innovation medicine. Tasly Pharma Group (600535) is listed on Shanghai Stock Exchange and generates revenue from drug sales across cardio-cerebrovascular, digestion and metabolism, tumor immunity, and neuroscience therapeutic areas.
2. Liquor Sales (Guotai): Guotai Digital Liquor Group, the second-largest liquor producer in Maotai Town, generates revenue from Daqu Maotai-flavor liquor sales. Tax-inclusive sales exceeded RMB 10 billion in 2021 with brand value surpassing RMB 200 billion in 2024.
3. Health Functional Foods: Products including Zhuoqing Instant Tea, Ginkgo Biloba Dropping Pills, Probiotic Powders, and ginseng-based supplements marketed through cardiovascular health, immunity, liver protection categories.
4. Tea Products (Depure): Revenue from scientific research, development, and sales of modern biological Pu'er tea, standardized production, and ready-to-drink Pu'er tea drinks and functional foods.
5. Mineral Water (C-Cell): Revenue from Cellular Vitality natural mineral water, 8L natural mineral water in bags, and 10L natural mineral water in boxes with taps, produced using pharmaceutical standards from Changbai Mountain mineral water resources.
6. Tasly Capital Investment Management: Asset management entity covering venture capital fund, PE fund, M&A fund, and asset management across the great health industry. Revenue generated from investment returns and capital management fees.
7. Digital Health Services: Internet hospital, chronic disease management platform, online health consultation, electronic health record management, and online pharmaceutical distribution through Juzhi Great Health Co., Ltd.
8. Cell & Gene Therapy: Cell therapy products leveraging mesenchymal stromal cells (MSCs) and immune cell platforms, with commercialization priority in China and international cell preparation centers in Japan and Australia.

Go-to-market motion3 records

Distribution channels8 records

Marketing channels7 records

Core offering

Tasly Holding Group is a high-tech conglomerate that develops, manufactures, and sells modern traditional Chinese medicine (TCM) pharmaceuticals, chemical drugs, and biological medicines through its listed subsidiary Tasly Pharma Group (600535). It also produces and sells premium consumer wellness products — Guotai Maotai-flavor liquor, Deepure Pu'er tea, and Cellular Vitality mineral water — and operates digital health services (internet hospital, chronic disease management) and an asset management platform (Tasly Capital).

Product overview

Tasly Holding Group is a high-tech enterprise group founded in 1994, focused on the 'Great Health' industry with bio-pharmaceutical, wellness & lifestyle products, and healthcare services. The portfolio includes Tasly Pharma Group (stock code: 600535) as the core pharmaceutical business, with products like Compound Danshen Dripping Pill and PuYouKe (PUK); sub-brands covering liquor (Guizhou Guotai Liquor), tea (Tasly Deepure Biological Tea), mineral water (Jilin Tasly Mineral Drinks), and digital health services (Juzhi Great Health). The group also operates Tasly Capital for health industry investment. Key therapeutic focus areas include cardio-cerebrovascular, tumor immunity, and neuroscience. The company integrates both wellness & lifestyle products and healthcare services across operations in Tianjin, Guizhou, Hebei, Yunnan, Jilin, Shaanxi, Hong Kong, Japan, and Australia.

Differentiator

Problem solved

Functional benefit

Brands

• Tasly Pharma: International modern Chinese medicine enterprise focused on medicine and health services
• Tasly Capital
• Tasly Bio-pharma
• Guotai Liquor
• Deepure
• Digital Herbal
• Tasly Healthpac
• Tasly Vivacare
• Juzhi Great Health

Products and services

• Compound Danshen Dripping Pill Modern Chinese medicine product for cardiovascular treatment that has completed FDA Phase III clinical trials and is entering the international mainstream market.
• PuYouKe (PUK) – Recombinant Human Urokinase for Injection National Class I biological medicine and the only approved listing recombinant human urokinase original product in China, positioned for cardiovascular and cerebrovascular therapy.
• Tasly Bio-pharma Portfolio (16 bio-pharmaceutical products) Innovative bio-pharmaceutical products spanning three therapeutic areas: cardio-cerebrovascular, tumor and autoimmune, and digestion and metabolism.
• Tasly Diyi Pharmaceutical Products (Chemical APIs and Solid Preparations) Chemical pharmaceutical products including APIs and oral solid preparations in anti-tumor, cardiovascular, mental health, and liver protection therapeutic areas, with EU, Korean, and Japanese GMP certifications.
• Guotai Daqu Maotai-flavor Liquor Authentic Daqu Maotai-flavor liquor produced by the second-largest government-licensed liquor enterprise in Maotai Town, with annual output of nearly 10,000 tons across three production bases.
• Deepure Biological Pu'er Tea Products Modern biological Pu'er tea products including standardized biological Pu'er tea and ready-to-drink Pu'er tea drinks with patented bioprocessing and digital extraction.
• Cellular Vitality Natural Mineral Water (C-Cell) Natural mineral water from Changbai Mountain, featuring patented small-molecule clustering technology with pH 8.5 mild alkalinity and over 20 minerals and trace elements, available in 8L bags and 10L boxes with taps.
• Ginkgo Biloba Dropping Pills Market-recognized health functional food product for cardiovascular health.
• Zhuoqing Instant Tea Market-recognized health functional food product for liver protection.
• Probiotic Powders Market-recognized health functional food product for immunity support.
• Digital Materia Medica (AI Model for TCM R&D) World's first AI model for traditional Chinese medicine R&D, enhancing efficiency in drug discovery and clinical decision-making while supporting preventive healthcare systems.
• Juzhi Great Health Digital Health Platform Internet technology platform providing online health consultation, online outpatient prescription renewal, online health management, online drug ordering, and chronic disease management platform.
• Digital Herbal Testing Services Third-party testing services for traditional Chinese medicine with a traceable, one-stop service system across a national laboratory area of more than 13,000 square meters, with CMA certification and CNAS accreditation.
• Tasly Hospital Healthcare Services High-end medical services including health examination, basic medical treatment, specialty medical treatment, family medical care, pediatrics, stomatology, traditional Chinese medicine, and ophthalmology, operated in cooperation with Tianjin Medical University General Hospital.
• Tasly Capital Investment Management Asset management platform covering the whole field of great health industry, integrating venture capital fund, PE fund, M&A fund, and asset management with a 4D 'patient-centered' investment model.

Quantifiable outcome

• Guotai Digital Liquor Group tax-inclusive sales exceeded RMB 10 billion in 2021
• +4 more outcomes

Named customers4 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature7 records

Partnerships

Nine partnerships are on record, tiered core, flagship, minor and major.

• Tokyo Lifestyle Co., Ltd.coreChannel Partner/ Reseller/ Distributor · 1 March 2026Tokyo Lifestyle signed a one-year master distribution agreement with TASLY (HONG KONG) INTERNATIONAL HOLDING COMPANY LIMITED for the distribution of health, cosmetics, and liquors starting March 1, 2026. The agreement aims to strengthen Tokyo Lifestyle's presence in China's health products market, with the company operating globally in regions including Japan, North America, and Southeast Asia.
• China Resources Pharmaceutical Group (CRP)flagshipStrategic or Co-development Partner · 4 August 2024China Resources Pharmaceutical Group and Tasly Pharmaceutical Industry Group signed a strategic partnership agreement on August 4, 2024, to conduct cooperation regarding innovation in Chinese medicinal formulation. This is a megamerger ongoing for Chinese medicinal formulation with CR reaching strategic partnership with Tasly.
• Huawei (Cloud Pangu Models)coreTechnology or Integration · 1 January 2024Huawei Developer Conference 2024 (HDC 2024) highlighted Tasly's 'large model of digital and intelligent herbs' based on Huawei Cloud Pangu Models 5.0, with innovative applications to the medical sector.
• International TCM PartnersminorStrategic or Co-development Partner · 1 January 2020Set up an International TCM Shared Platform and carried out international academic exchanges on jointly fighting COVID-19 with international partners in 2020.
• Arbor Company (USA)majorStrategic or Co-development Partner · 1 January 2018Signed T89 R&D and marketing cooperation with Arbor Company in the United States in 2018. T89 is Tasly's Compound Danshen Dripping Pill being developed for the international market.
• Tianjin Medical University General HospitalmajorStrategic or Co-development PartnerTasly Hospital is operated in cooperation with Tianjin Medical University General Hospital and several large medical institutions in Tianjin, providing health examination, basic medical treatment, specialty medical treatment, and family medical care.
• Cell Preparation Partners (Japan & Australia)coreStrategic or Co-development PartnerTasly has established cell preparation centers in Japan and Australia, working closely with local clinics to accelerate the clinical adoption of stem cell therapies internationally.
• Guizhou Guotai Liquor Distribution NetworkcoreChannel Partner/ Reseller/ DistributorGuotai Liquor's three production bases (Guotai Wine Industry, Guotai Winery, and Guotai Huaijiu) operate with established distribution networks for Maotai-flavor liquor across China.
• Supply Chain and Livestream Commerce PartnersminorGTM or Marketing PartnerTasly integrates online and offline channels, building an open innovation platform that connects with global partners in supply chain management, livestream commerce, and content marketing.

Scale indicators11 records

Recent moves6 records

Expansion highlights8 records

Direct peers

• Beijing Tongrentang: Historic Chinese traditional medicine brand with pharmaceutical manufacturing, retail pharmacy chains, and healthcare services. Directly comparable to Tasly's TCM pharma core and integrated health management strategy.
• Kweichow Moutai: China's largest Maotai-flavor baijiu producer and the dominant premium liquor brand. Direct competitor to Tasly's Guotai Liquor segment in the Daqu Maotai-flavor category and provides a valuation benchmark for Tasly's liquor business.
• Pien Tze Huang: Premium Chinese traditional medicine brand with pharmaceutical manufacturing and healthcare product portfolio. Comparable to Tasly in being a high-end TCM brand with consumer recognition and pharma R&D pipeline.
• China Resources Pharmaceutical Group: State-owned pharmaceutical conglomerate and Tasly's announced strategic merger partner (August 2024). Highly relevant as the direct counterparty in Tasly's most consequential ongoing transaction and a benchmark for Chinese TCM scale.
• Yunnan Baiyao Group: Leading Chinese traditional Chinese medicine and consumer healthcare conglomerate. Highly comparable to Tasly as a diversified 'pan-health' group combining modernized TCM, OTC consumer products, and a listed pharma subsidiary with a substantial traditional medicine franchise.
• Shanghai Pharmaceuticals Holding: Major Chinese pharmaceutical conglomerate combining research, manufacturing, distribution, and retail pharmacy operations. Comparable to Tasly's vertically integrated pharma-plus-distribution model and global subsidiary footprint.
• China Traditional Chinese Medicine Holdings: Sinopharm-affiliated TCM manufacturer focused on modernized Chinese medicine formulations. Directly comparable to Tasly Pharma Group as a TCM-focused pharma player with national distribution and state-backed partnerships.
• Guangzhou Pharmaceutical Holdings (GPHL): Large state-owned Chinese pharmaceutical group combining TCM brands (e.g., Wanglaoji herbal tea) with Western pharma manufacturing. Comparable to Tasly in scale, TCM heritage, and cross-category consumer health positioning.

Broad incumbents

• Sino Biopharmaceutical Limited: Hong Kong-listed Chinese pharmaceutical group spanning innovative drugs, biologics, and TCM. Comparable to Tasly Bio-pharma in therapeutic breadth across cardio-cerebrovascular, oncology, and digestive areas.
• Wuliangye Yibin: Major Chinese baijiu producer competing with Guotai Liquor in the broader premium liquor category. Comparable as a benchmark for premium Chinese liquor scale, brand value, and consumer market dynamics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks7 records

Customer concentration

• LinkedInlinkedin.com/company/tasly

Compliance10 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries15 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments21 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tasly Holding Group